bladder cancer

News

NICE axes funding for MSD's Keytruda in bladder cancer despi...

NICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal from the company.

News

Roche's Tecentriq loses bladder cancer use as FDA crackdown ...

Roche's Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that have failed to live up to their early promise.

News

AZ withdraws Imfinzi in US bladder cancer use after trial fa...

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer indication in the US.

News

Astellas/Seagen prepare full US filing of bladder cancer dru...

Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend.

News

Merck, Pfizer get EU nod for Bavencio as bladder cancer main...

Pfizer and partner Merck KGaA now have approval on both sides of the Atlantic for their checkpoint inhibitor Bavencio as a first-line maintenance therapy for bladder cancer, stealing a marc

News

AZ aims to cut cancer clinic visits with new Imfinzi regimen

The FDA is to review data supporting AstraZeneca’s Imfinzi (durvalumab) cancer immunotherapy in a new four-week regimen that will halve the number of required clinic visits for patients wit

NICE axes funding for MSD's Keytruda in bladder cancer despi...

Roche's Tecentriq loses bladder cancer use as FDA crackdown ...

AZ withdraws Imfinzi in US bladder cancer use after trial fa...

Astellas/Seagen prepare full US filing of bladder cancer dru...

Merck, Pfizer get EU nod for Bavencio as bladder cancer main...

AZ aims to cut cancer clinic visits with new Imfinzi regimen

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

bladder cancer

Editor's Picks